Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

Little Green Pharma winds down German distribution deal

  • In News
  • November 21, 2022
  • Jack Cornips
Little Green Pharma winds down German distribution deal

A key player in the global cannabis market, Little Green Pharma (ASX: LGP), has pulled the plug on its German distributor, Four 20 Pharma GmbH, after failing to meet the contract terms to bring a highly-prospective new THC strain to the German medical cannabis market by 19th November 2022.

Licensed as a manufacturer, wholesaler, and importer of medical cannabis, Four 20 Phama entered into a 2.5 year take-or-pay agreement with Little Green Pharma earlier this year on 19 May 2022 to on-board a high-THC cannabis strain for distribution across Germany. 

The strain, which contains THC levels of >25% (much more than usual strains), was bought during a tightly-executed bidding process by LGP with an aim to get the new product in front of a range of potential new distribution partners. 

The deal between the two represented a minimum take-or-payment obligation of at least $7.5 million over 30 months, including any payment to balance fees and to defray strain development costs. 

As part of the contract, Four 20 committed themselves to secure approvals from German regulators before an agreed satisfaction date of Saturday 19th November 2022, which they failed to meet nor did they attempt to extend to allow for more time. 

As such, Four 20 did not fulfil the agreed undertakings, and on that account, Little Green Pharma served a notice of default and has considered offering the strain via its own existing distribution channels across Germany.

In a separate announcement, the Company mentioned that they have received confirmation from the French Government to extend the period of the two-year French medical cannabis trial for a further 12 months until March 2024.

The trial is part of a two-year nationwide experiment in France that is primarily designed to evaluate the best conditions of access to medical cannabis.

The company says it has been in negotiations with the French Government in relation to an earlier request for its continued participation in the trial, given that LGP is the largest supplier of products and has been providing cannabis to participants free of charge.

  • About
  • Latest Posts
Jack Cornips
Trading Desk Assistant at Emerald Financial
Latest posts by Jack Cornips (see all)
  • UNITH delivers eSocial Worker for public health services across 14 countries - December 5, 2023
  • Novatti cashing out of Reckon investment, clears debt to simplify payments business - November 17, 2023
  • Novatti seizes opportunity in Australia’s cashless transition as revenues rise while expenses drop - October 30, 2023
  •  
  •  
  •  
  •  
  • asx lgp
  • cannabis
  • THC
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Jack Cornips
Trading Desk Assistant at Emerald Financial
Latest posts by Jack Cornips (see all)
  • UNITH delivers eSocial Worker for public health services across 14 countries - December 5, 2023
  • Novatti cashing out of Reckon investment, clears debt to simplify payments business - November 17, 2023
  • Novatti seizes opportunity in Australia’s cashless transition as revenues rise while expenses drop - October 30, 2023

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Jack Cornips
Trading Desk Assistant at Emerald Financial
Latest posts by Jack Cornips (see all)
  • UNITH delivers eSocial Worker for public health services across 14 countries - December 5, 2023
  • Novatti cashing out of Reckon investment, clears debt to simplify payments business - November 17, 2023
  • Novatti seizes opportunity in Australia’s cashless transition as revenues rise while expenses drop - October 30, 2023
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.